Reuters logo
BRIEF-Almirall announces data from pivotal phase-3 clinical trials with inhibitor to treat psoriasis
October 3, 2016 / 6:16 AM / in a year

BRIEF-Almirall announces data from pivotal phase-3 clinical trials with inhibitor to treat psoriasis

Oct 3 (Reuters) - Almirall SA :

* Announces results from two pivotal phase-3 clinical trials (reSURFACE 1 and 2) achieving primary endpoint of Tildrakizumab, an investigational IL-23p19 inhibitor, in patients with moderate-to-severe plaque psoriasis Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below